Beyond antibiotic duration in acute cholangitis: system-level determinants after biliary drainage

BACKGROUND: The COBRA trial addresses whether antibiotic exposure can be safely reduced after adequate biliary drainage in acute cholangitis. We argue that antibiotic duration should be interpreted within the broader care pathway in which treatment is delivered, because source control, device management, host susceptibility, local microbiological ecology, and reliability of care processes may modify clinical outcomes. MAIN BODY: Drawing on the Medical Research Council framework for complex interventions, we propose a system-level interpretation that complements, rather than replaces, the randomized comparison of antibiotic duration. A 24-month single-center quasi-experimental study in a gastroenterology unit, recently accepted for publication, provides hypothesis-generating support for this perspective: implementation of a standardized and traceable work-support intervention was associated with reductions in healthcare-associated infections, ward microbial pressure, and clinically expressed microbial burden. These findings do not establish causality or determine optimal antibiotic duration in acute cholangitis. To make care-pathway variability more explicit in future studies, we propose a Bundle Deviation Score based on six domains: timely diagnosis, timing of biliary drainage, adequacy of drainage and source control, antimicrobial strategy, device management, and standardized high-contact care. This contextual process measure could complement patient-centered outcome frameworks such as Desirability of Outcome Ranking by distinguishing treatment effects from variability in how care is delivered. CONCLUSIONS: The COBRA trial provides important evidence for antimicrobial stewardship after biliary drainage. Its interpretation and transferability may be strengthened by measuring the reliability of the broader care pathway alongside antibiotic duration. Prospective validation is required before the proposed Bundle Deviation Score can be used for clinical or research applications.

Authors

Institutions

Publication Details

Journal
Trials
Published
2026-09-16
DOI
https://doi.org/10.1186/s13063-026-09975-y
Primary Topic
Gallbladder and Bile Duct Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Beyond antibiotic duration in acute cholangitis: system-level determinants after biliary drainage

F. Bronte, Linda Pasta, Emma Aragona
Trials
Gallbladder and Bile Duct Disorders
article

Beyond antibiotic duration in acute cholangitis: system-level determinants after biliary drainage

F. Bronte, Linda Pasta, Emma Aragona
article en

Abstract

BACKGROUND: The COBRA trial addresses whether antibiotic exposure can be safely reduced after adequate biliary drainage in acute cholangitis. We argue that antibiotic duration should be interpreted within the broader care pathway in which treatment is delivered, because source control, device management, host susceptibility, local microbiological ecology, and reliability of care processes may modify clinical outcomes. MAIN BODY: Drawing on the Medical Research Council framework for complex interventions, we propose a system-level interpretation that complements, rather than replaces, the randomized comparison of antibiotic duration. A 24-month single-center quasi-experimental study in a gastroenterology unit, recently accepted for publication, provides hypothesis-generating support for this perspective: implementation of a standardized and traceable work-support intervention was associated with reductions in healthcare-associated infections, ward microbial pressure, and clinically expressed microbial burden. These findings do not establish causality or determine optimal antibiotic duration in acute cholangitis. To make care-pathway variability more explicit in future studies, we propose a Bundle Deviation Score based on six domains: timely diagnosis, timing of biliary drainage, adequacy of drainage and source control, antimicrobial strategy, device management, and standardized high-contact care. This contextual process measure could complement patient-centered outcome frameworks such as Desirability of Outcome Ranking by distinguishing treatment effects from variability in how care is delivered. CONCLUSIONS: The COBRA trial provides important evidence for antimicrobial stewardship after biliary drainage. Its interpretation and transferability may be strengthened by measuring the reliability of the broader care pathway alongside antibiotic duration. Prospective validation is required before the proposed Bundle Deviation Score can be used for clinical or research applications.

TrialsVol. 27(1)
Laboratoire Pluridisciplinaire de Recherche en Ingénierie des Systèmes, Mécanique et Energétique (FR), Ospedale Vincenzo Cervello (IT), University of Palermo (IT)
Zero hunger
Openalex Percentile: Top 13%
Gallbladder and Bile Duct Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.